Friday, May 27, 2016
Roche Holding AG said on Friday its drug Gazyva showed superior progression-free survival compared to Mabthera/Rituxan in people with previously untreated follicular lymphoma in the pivotal phase III Gallium study that met is primary endpoint early.
Results from an interim analysis showed that the Gazyva-based treatment significantly reduced the risk of the disease worsening or death compared to the MabThera/Rituxan-based treatment, Roche said in a statement.
Follicular lymphoma is considered incurable and relapse is common. It is estimated that more than 75,000 people are diagnosed with this most common form of non-Hodgkin lymphoma each year worldwide, Roche said.
Source : reuters.com
